AURORA CANNABIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.19 USD | +0.65% |
|
-7.06% | +29.99% |
| 05-16 | US Government Reclassifies Marijuana to Less-Restrictive Category | MT |
| 05-16 | Justice Department Set to Post Cannabis Reclassification Plans | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.99% | 337M | - | ||
| +37.29% | 6.02B | B- | ||
| -21.28% | 4.19B | C+ | ||
| +4.52% | 3.25B | C | ||
| -18.16% | 2.87B | B- | ||
| -7.70% | 2.37B | - | D+ | |
| +41.50% | 1.89B | - | ||
| -4.05% | 1.58B | - | - | |
| -15.56% | 1.54B | - | - | |
| -14.62% | 1.5B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ACB Stock
- ACB Stock
- Ratings Aurora Cannabis Inc.
